|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD).
|
25457617 |
2015 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared.
|
21282580 |
2011 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that sFLT-1, an endogenous inhibitor of vascular endothelial growth factor A (VEGF-A), is synthesized by photoreceptors and retinal pigment epithelium (RPE), and is decreased in human AMD.
|
23795287 |
2013 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD).
|
31055948 |
2019 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the presented data reveal that gene therapy targeting VEGFA via multigenic AAV vectors displays combined efficacy, suggesting that dual-acting therapy is an important tool in future eye gene therapy for the treatment of neovascular ocular diseases, including AMD.
|
30825671 |
2019 |
|
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) expression induces age-related macular degeneration (AMD), which is a common vision-threatening disease due to choroidal neovascularization and a fibrovascular membrane.
|
30200369 |
2018 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four CNV candidate regions located in AMD-relevant genes (VEGFA, ARMS2/HTRA1, CFH and VLDLR), were selected based on the outcomes of our previous study which elucidated common CNVs in the Asian populations.
|
22355348 |
2012 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Intravitreal ranibizumab, which neutralizes vascular endothelial growth factor (VEGF), nowadays constitutes the first-line treatment in neovascular age-related macular degeneration (AMD).
|
21830945 |
2011 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies of comprehensive VEGF gene variations are required to characterize the susceptibility of the VEGF gene in the pathogenesis of AMD.
|
20847577 |
2011 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we describe a deep sequencing-aided engineering strategy to fine-tune the specificity of an angiopoietin-2 (Ang2)/vascular endothelial growth factor (VEGF) dual action Fab, 5A12.1 for the treatment of age-related macular degeneration.
|
28585908 |
2019 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
LHGDN |
We undertook a case-control association study to investigate the VEGF-A gene, a known angiogenic gene that has previously been associated with AMD.
|
18079689 |
2007 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
The up-regulation of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), is intimately linked to the pathogenesis of exudative AMD, and its antagonism has been effectively targeted for treatment.
|
28679845 |
2017 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD.
|
29446046 |
2018 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, 224 anti-VEGF naïve subjects including 56 patients in early AMD group, 56 patients in intermediate AMD group, 56 patients in neovascular AMD group and 56 patients in no AMD group were recruited.
|
30594908 |
2018 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
This is the most extensive analysis of the VEGF gene in AMD, demonstrating a clear association with the exudative form of disease, thereby creating the possibility for predictive testing.
|
16940309 |
2006 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of treatment assignment (intravitreal aflibercept vs ranibizumab) and baseline characteristics with fellow eye conversion to nAMD in the VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies.
|
31294771 |
2019 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Malondialdehyde induces autophagy dysfunction and VEGF secretion in the retinal pigment epithelium in age-related macular degeneration.
|
26923802 |
2016 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have analysed if polymorphisms in genes coding for VEGFA and VEGFR are associated to susceptibility to suffer AMD in a cohort of Spanish subjects.
|
23971975 |
2013 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD.
|
12597922 |
2003 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This showed an association with the well-established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)-HTRA1 (HtrA serine peptidase 1) (P =2.7 × 10(-72)), CFH (complement factor H) (P =2.3 × 10(-47)), C2 (complement component 2)-CFB (complement factor B) (P =5.2 × 10(-9)), C3 (complement component 3) (P =2.2 × 10(-3)) and CFI (P =3.6 × 10(-3)) and with more recently reported risk loci at VEGFA (P =1.2 × 10(-3)) and LIPC (hepatic lipase) (P =0.04).
|
22694956 |
2012 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Controlling the balance of VEGF(xxx) to VEGF(xxx) isoforms may therefore be therapeutically valuable in the treatment of proliferative eye diseases such as diabetic retinopathy and age related macular degeneration.
|
16735996 |
2006 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we tested the hypothesis that VEGF gene polymorphisms play a role in the treatment success with VEGF inhibitors in patients with exudative AMD.
|
22521084 |
2012 |
|
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine serum vascular endothelial growth factor 165 (VEGF165) levels and the association of the complement factor H gene (CFH) Y402H polymorphism in patients with exudative age-related macular degeneration (AMD) in comparison to unaffected control subjects.
|
21158586 |
2011 |
|
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, LV-delivered microRNAs targeting the Vegfa gene in RPE cells reduced the size of laser-induced CNV in mice 28 days PI, as a consequence of diminished VEGF levels, suggesting that LVs delivered locally are powerful tools in the development of gene therapy-based strategies for treatment of age-related macular degeneration.
|
28817343 |
2017 |
|
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy.
|
28557591 |
2018 |